|
FDA Advisory Panel Recommends Aegerion’s Lomitapide to Treat HoFH
Despite liver toxicity concerns, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13–2 to recommend approval of Aegerion Pharmaceuticals’ lomitapide.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives